Steady incremental advances in research and development are vital to positively impact the way cancer is treated. In 1975, fewer than half of people diagnosed with cancer survived five years. Today, two out of three people diagnosed with cancer survive at least five years, thanks to advances in oncology drugs and treatment protocols.
Diverse Biotech’s team is actively pursuing breakthroughs in cancer-drug development through laboratory research and through our multiple FDA oncology clinical trials that are soon to be enrolling participants.
Our formulas are novel discoveries developed to help cancer patients by changing the standard of care in oncology. Through additional research and development, we strive to improve health and improve the lives of patients facing the most significant health challenges, like cancer and neurological disease.
Operating through the FDA New Drug Application process, we continue to focus our research on conditions that represent some of todays most significant health challenges like cancer and neurological disease. At Diverse Pharma, this division’s team combines their experience, scientific research and business acumen to do more of what they are passionate about: improving health the well-being of millions of people.
With multiple active FDA clinical trials in oncology, the Diverse Pharma division of Diverse Biotech propels our novel cannabinoid discoveries, for improving the health and well being of cancer patients around the world, through the FDA approval process.
Diverse Biotech currently holds dozens of patents/patents pending for treatments of cancer and has multiple active FDA Clinical Trials in oncology. Our research in glioblastoma multiforme, basal cell and squamous cell carcinomas, multiple myeloma, gastrointestinal cancers, and breast cancer is aligned with the FDA’s primary clinical stage focus.
Cannabinoids have been shown to cause antitumor effects by various mechanisms, including: